Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.49 |
| ▸ | HTR2A | P28223 | 10/20 | 0.49 |
| ▸ | HTR2C | P28335 | 8/20 | 0.49 |
| ▸ | DTYMK | P23919 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23915630 | 0.90 | MAPT (0.54) | NPC1LMNANR2F2HTTSMN1; SMN2 | |
| SCHEMBL23966843 | 0.88 | ALOX15 (0.51) | NPC1LMNANR2F2HTTSMN1; SMN2 | |
| SCHEMBL23966581 | 0.87 | SLC6A4 (0.46) | LMNASMN1; SMN2SLC6A4HTR2AHTR2C | |
| SCHEMBL23915515 | 0.84 | NPC1 (0.49) | NPC1LMNANR2F2HTTSMN1; SMN2 | |
| SCHEMBL23966582 | 0.82 | SLC6A4 (0.48) | SLC6A4HTR2AHTR2CRECQL | |
| SCHEMBL23915623 | 0.82 | RECQL (0.47) | NPC1LMNANR2F2HTTSMN1; SMN2 | |
| SCHEMBL23915513 | 0.80 | NPC1 (0.46) | NPC1LMNANR2F2HTTSMN1; SMN2 | |
| SCHEMBL23914934 | 0.80 | LMNA (0.51) | NPC1LMNANR2F2HTTSMN1; SMN2 | |
| SCHEMBL23909042 | 0.79 | TSHR (0.55) | SMN1; SMN2RECQL | |
| SCHEMBL23915514 | 0.77 | SMN1; SMN2 (0.48) | NPC1LMNANR2F2HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | NPC1 467/4885LMNA 449/4885NR2F2 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.